{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:20:38Z","timestamp":1742962838998,"version":"3.40.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,25]]},"DOI":"10.7759\/cureus.81182","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T20:26:37Z","timestamp":1742934397000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Selpercatinib in Non-small Cell Lung Cancer With Bilateral Internal Auditory Canal Metastases: A Case Report"],"prefix":"10.7759","author":[{"given":"Diana","family":"Moreira-Sousa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria S.","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks LE","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al.. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023, 34:339-57. 10.1016\/j.annonc.2022.12.009","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611715","article-title":"Targeted therapeutic options in early and metastatic NSCLC-overview","volume":"30","author":"G\u00e1lffy G","year":"2024","unstructured":"G\u00e1lffy G, Mor\u00f3cz \u00c9, Korompay R, et al.. Targeted therapeutic options in early and metastatic NSCLC-overview. Pathol Oncol Res. 2024, 30:1611715. 10.3389\/pore.2024.1611715","journal-title":"Pathol Oncol Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122205","article-title":"Promising combinatorial therapeutic strategies against non-small cell lung cancer","volume":"16","author":"Kaur P","year":"2024","unstructured":"Kaur P, Singh SK, Mishra MK, Singh S, Singh R. Promising combinatorial therapeutic strategies against non-small cell lung cancer. Cancers (Basel). 2024, 16:10.3390\/cancers16122205","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1033484","article-title":"Targeted therapy of RET fusion-positive non-small cell lung cancer","volume":"12","author":"Shen Z","year":"2022","unstructured":"Shen Z, Qiu B, Li L, Yang B, Li G. Targeted therapy of RET fusion-positive non-small cell lung cancer. Front Oncol. 2022, 12:1033484. 10.3389\/fonc.2022.1033484","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta K","year":"2014","unstructured":"Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, Furuta K, Kushima R. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer. 2014, 110:1571-8. 10.1038\/bjc.2014.36","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang R","year":"2012","unstructured":"Wang R, Hu H, Pan Y, et al.. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012, 30:4352-9. 10.1200\/JCO.2012.44.1477","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon A","year":"2018","unstructured":"Drilon A, Lin JJ, Filleron T, et al.. Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol. 2018, 13:1595-601. 10.1016\/j.jtho.2018.07.004","journal-title":"J Thorac Oncol"},{"key":"ref8","unstructured":"European Medicines Agency. Retsevmo. EPAR - Product information. (2021). Accessed: January 02, 2025: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/retsevmo-epar-product-information_en.pdf.."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S460147","article-title":"Libretto-431: Confirming the superiority of selpercatinib to chemotherapy and the lack of efficacy of immune checkpoint inhibitors in advanced RET fusion-positive (RET+) NSCLC, another unique never-smoker predominant molecular subtype of NSCLC","volume":"15","author":"Lee AT","year":"2024","unstructured":"Lee AT, Ou SI. Libretto-431: Confirming the superiority of selpercatinib to chemotherapy and the lack of efficacy of immune checkpoint inhibitors in advanced RET fusion-positive (RET+) NSCLC, another unique never-smoker predominant molecular subtype of NSCLC. Lung Cancer (Auckl). 2024, 15:75-80. 10.2147\/LCTT.S460147","journal-title":"Lung Cancer (Auckl)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam F","year":"2019","unstructured":"Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, Bukhari N. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019, 12:728-36. 10.1159\/000503095","journal-title":"Case Rep Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw P","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al.. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016, 11:39-51. 10.1016\/j.jtho.2015.09.009","journal-title":"J Thorac Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2015.06.002","article-title":"High rate of bilaterality in internal auditory canal metastases","volume":"36","author":"Chang MT","year":"2015","unstructured":"Chang MT, Michaelides EM. High rate of bilaterality in internal auditory canal metastases. Am J Otolaryngol. 2015, 36:798-804. 10.1016\/j.amjoto.2015.06.002","journal-title":"Am J Otolaryngol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00021","article-title":"Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases","volume":"3","author":"Guo R","year":"2019","unstructured":"Guo R, Schreyer M, Chang JC, et al.. Response to selective RET inhibition with LOXO-292 in a patient with RET fusion-positive lung cancer with leptomeningeal metastases. JCO Precis Oncol. 2019, 3:10.1200\/PO.19.00021","journal-title":"JCO Precis Oncol"},{"key":"ref15","unstructured":"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3). (2025). Accessed. March 22, 2025: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf.."},{"key":"ref16","unstructured":"National Comprehensive Cancer Network. Central Nervous System Cancers (Version 5). (2024). Accessed. March 22, 2025: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf.."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon A","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DS, et al.. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020, 383:813-24. 10.1056\/NEJMoa2005653","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/346533-efficacy-of-selpercatinib-in-non-small-cell-lung-cancer-with-bilateral-internal-auditory-canal-metastases-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T20:26:40Z","timestamp":1742934400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/346533-efficacy-of-selpercatinib-in-non-small-cell-lung-cancer-with-bilateral-internal-auditory-canal-metastases-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.81182","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}